cardiology Flashcards
what is Wolff-Parkinson White (WPW) syndrome
Wolff-Parkinson White (WPW) syndrome is caused by a congenital accessory conducting pathway between the atria and ventricles leading to a atrioventricular re-entry tachycardia (AVRT). As the accessory pathway does not slow conduction AF can degenerate rapidly to VF
ecg features of Wolff-Parkinson White (WPW) syndrome
Possible ECG features include:
short PR interval wide QRS complexes with a slurred upstroke - 'delta wave' left axis deviation if right-sided accessory pathway* right axis deviation if left-sided accessory pathway* *in the majority of cases, or in a question without qualification, Wolff-Parkinson-White syndrome is associated with left axis deviation
Differentiating between type A and type B
type A (left-sided pathway): dominant R wave in V1 type B (right-sided pathway): no dominant R wave in V1
associations of Wolff-Parkinson White (WPW) syndrome
Associations of WPW
hypertrophic cardiomyopathy mitral valve prolapse Ebstein's anomaly thyrotoxicosis secundum ASD
what is Ebstein’s anomaly
Ebstein’s anomaly is a congenital heart defect in which the septal and posterior leaflets of the tricuspid valve are displaced towards the apex of the right ventricle of the heart.
management of Wolff-Parkinson White (WPW) syndrome
Management
definitive treatment: radiofrequency ablation of the accessory pathway medical therapy: sotalol**, amiodarone, flecainide
**sotalol should be avoided if there is coexistent atrial fibrillation as prolonging the refractory period at the AV node may increase the rate of transmission through the accessory pathway, increasing the ventricular rate and potentially deteriorating into ventricular fibrillation
The European Society of Cardiology published updated guidelines on the management of atrial fibrillation in 2012. They suggest using the CHA2DS2-VASc score to determine the most appropriate anticoagulation strategy. This scoring system superceded the CHADS2 score. what are its contents and recommended anticoagulations
C Congestive heart failure 1 H Hypertension (or treated hypertension) 1 A2 Age >= 75 years 2 D Diabetes 1 S2 Prior Stroke or TIA 2 V Vascular disease (including ischaemic heart disease and peripheral arterial disease) 1 A Age 65-74 years 1 S Sex (female) 1
0 No treatment is preferred to aspirin
1 Oral anticoagulants preferred to aspirin; dabigatran is an alternative
2 or more Oral anticoagulants; dabigatran is an alternative
what drugs are used to cardiovert someone in AF?
The Royal College of Physicians and NICE published guidelines on the management of atrial fibrillation (AF) in 2006. The following is also based on the joint American Heart Association (AHA), American College of Cardiology (ACC) and European Society of Cardiology (ESC) 2012 guidelines
Agents with proven efficacy in the pharmacological cardioversion of atrial fibrillation
amiodarone flecainide (if no structural heart disease) others (less commonly used in UK): quinidine, dofetilide, ibutilide, propafenone
Less effective agents
beta-blockers (including sotalol) calcium channel blockers digoxin disopyramide procainamide
why did the guidelines on the diagnosis of hypertension change in 2011
It has long been recognised by doctors that there is a subgroup of patients whose blood pressure climbs 20 mmHg whenever they enter a clinical setting, so called ‘white coat hypertension’. If we just rely on clinic readings then such patients may be diagnosed as having hypertension when the vast majority of time there blood pressure is normal.
This has led to the use of both ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM) to confirm the diagnosis of hypertension. These techniques allow a more accurate assessment of a patients’ overall blood pressure. Not only does this help prevent overdiagnosis of hypertension - ABPM has been shown to be a more accurate predictor of cardiovascular events than clinic readings.
hypertension classification
Stage 1 hypertension Clinic BP >= 140/90 mmHg and subsequent ABPM daytime average or HBPM average BP >= 135/85 mmHg
Stage 2 hypertension Clinic BP >= 160/100 mmHg and subsequent ABPM daytime average or HBPM average BP >= 150/95 mmHg
Severe hypertension Clinic systolic BP >= 180 mmHg, or clinic diastolic BP >= 110 mmHg
diagnosis of hypertension
Firstly, NICE recommend measuring blood pressure in both arms when considering a diagnosis of hypertension.
If the difference in readings between arms is more than 20 mmHg then the measurements should be repeated. If the difference remains > 20 mmHg then subsequent blood pressures should be recorded from the arm with the higher reading.
It should of course be remember that there are pathological causes of unequal blood pressure readings from the arms, such as supravalvular aortic stenosis. It is therefore prudent to listen to the heart sounds if a difference exists and further investigation if a very large difference is noted.
NICE also recommend taking a second reading during the consultation, if the first reading is > 140/90 mmHg. The lower reading of the two should determine further management.
NICE suggest offering ABPM or HBPM to any patient with a blood pressure >= 140/90 mmHg.
If however the blood pressure is >= 180/110 mmHg:
immediate treatment should be considered if there are signs of papilloedema or retinal haemorrhages NICE recommend same day assessment by a specialist NICE also recommend referral if a phaeochromocytoma is suspected (labile or postural hypotension, headache, palpitations, pallor and diaphoresis)
Ambulatory blood pressure monitoring (ABPM)
at least 2 measurements per hour during the person's usual waking hours (for example, between 08:00 and 22:00) use the average value of at least 14 measurements
If ABPM is not tolerated or declined HBPM should be offered.
Home blood pressure monitoring (HBPM)
for each BP recording, two consecutive measurements need to be taken, at least 1 minute apart and with the person seated BP should be recorded twice daily, ideally in the morning and evening BP should be recorded for at least 4 days, ideally for 7 days discard the measurements taken on the first day and use the average value of all the remaining measurements
Interpreting the results
ABPM/HBPM >= 135/85 mmHg (i.e. stage 1 hypertension)
treat if < 80 years of age AND any of the following apply; target organ damage, established cardiovascular disease, renal disease, diabetes or a 10-year cardiovascular risk equivalent to 20% or greater
ABPM/HBPM >= 150/95 mmHg (i.e. stage 2 hypertension)
offer drug treatment regardless of age
what drugs have been shown to improve mortality in patients with chronic heart failure
A number of drugs have been shown to improve mortality in patients with chronic heart failure:
ACE inhibitors (SAVE, SOLVD, CONSENSUS) spironolactone (RALES) beta-blockers (CIBIS) hydralazine with nitrates (VHEFT-1)
No long-term reduction in mortality has been demonstrated for loop diuretics such as furosemide.
NICE issued updated guidelines on management of heart failure in 2010, key points include:
NICE issued updated guidelines on management in 2010, key points include:
first-line treatment for all patients is both an ACE-inhibitor and a beta-blocker second-line treatment is now either an aldosterone antagonist, angiotensin II receptor blocker or a hydralazine in combination with a nitrate if symptoms persist cardiac resynchronisation therapy or digoxin* should be considered diuretics should be given for fluid overload offer annual influenza vaccine offer one-off** pneumococcal vaccine
*digoxin has also not been proven to reduce mortality in patients with heart failure. It may however improve symptoms due to its inotropic properties. Digoxin is strongly indicated if there is coexistent atrial fibrillation
**adults usually require just one dose but those with asplenia, splenic dysfunction or chronic kidney disease need a booster every 5 years
Features of severe aortic stenosis
Features of severe aortic stenosis
narrow pulse pressure slow rising pulse delayed ESM soft/absent S2 S4 thrill duration of murmur left ventricular hypertrophy or failure
Causes of aortic stenosis
Causes of aortic stenosis
degenerative calcification (most common cause in older patients > 65 years) bicuspid aortic valve (most common cause in younger patients < 65 years) William's syndrome (supravalvular aortic stenosis) post-rheumatic disease subvalvular: HOCM
Management of aortic stenosis
Management
if asymptomatic then observe the patient is general rule if symptomatic then valve replacement if asymptomatic but valvular gradient > 50 mmHg and with features such as left ventricular systolic dysfunction then consider surgery balloon valvuloplasty is limited to patients with critical aortic stenosis who are not fit for valve replacement
The management of stable angina comprises lifestyle changes, medication, percutaneous coronary intervention and surgery. NICE produced guidelines in 2011 covering the management of stable angina - what are they?
all: 1 - aspirin 2 - statin 3 - GTN 4 - beta blocker or CCB (rate limiting)
then
1 - max dose BB or CCB eg atenolol 100mg OD
2 - then CCB AND BB
if a patient is on monotherapy and cannot tolerate the addition of a calcium channel blocker or a beta-blocker then consider one of the following drugs: a long-acting nitrate, ivabradine, nicorandil or ranolazine if a patient is taking both a beta-blocker and a calcium-channel blocker then only add a third drug whilst a patient is awaiting assessment for PCI or CABG
problems with nitrate tolerance in anti anginal medication routines
Nitrate tolerance
many patients who take nitrates develop tolerance and experience reduced efficacy the BNF advises that patients who develop tolerance should take the second dose of isosorbide mononitrate after 8 hours, rather than after 12 hours. This allows blood-nitrate levels to fall for 4 hours and maintains effectiveness this effect is not seen in patients who take modified release isosorbide mononitrate
use of ivabradine in angina
Ivabradine
a new class of anti-anginal drug which works by reducing the heart rate acts on the If ('funny') ion current which is highly expressed in the sinoatrial node, reducing cardiac pacemaker activity adverse effects: visual effects, particular luminous phenomena, are common. Bradycardia, due to the mechanism of action, may also be seen there is no evidence currently of superiority over existing treatments of stable angina
when are J waves seen on an ECG
J waves are seen in hypothermia
when are delta waves seen on an ECG
delta waves are associated with Wolff Parkinson White syndrome.
when are U waves seen on an ECG
Hypokalaemia - U waves on ECG
ECG features of hypokalaemia
U waves small or absent T waves (occasionally inversion) prolong PR interval ST depression long QT
what happens to a person in ventricular fibrillation
if the patient is conscious ventricular fibrillation (VF) can be excluded - the nature of VF means that it is not compatible with a cardiac output.
what is Ventricular tachycardia
Ventricular tachycardia (VT) is broad-complex tachycardia originating from a ventricular ectopic focus. It has the potential to precipitate ventricular fibrillation and hence requires urgent treatment.
There are two main types of VT:
monomorphic VT: most commonly caused by myocardial infarction
polymorphic VT: A subtype of polymorphic VT is torsades de pointes which is precipitated by prolongation of the QT interval.